Glenmark Pharmaceuticals FY25 Annual Earnings Summary
4 quarters covered · ₹13,322 Cr revenue · ₹1,046 Cr PAT · 8.9% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Risks flagged during the year
Monroe facility has an FDA meeting in September 2024, but no restart timeline; Goa remediation completed but inspection pending. Delays could impact US launches.
Q2 FY25 · highMonroe plant has been non-operational; any further delay in FDA clearance could prolong the $25-26M annual cash burn.
Q3 FY25 · highThe Monroe facility is awaiting FDA inspection, delaying potential revenue from injectable products. Management has limited visibility on timing.
Q4 FY25 · highPithampur plant under FDA discussion; Monroe plant awaiting inspection. Delays could impact U.S. launch timelines.
Q4 FY25 · highISB 2001 licensing deal is critical to fund IGI's $70M annual burn; any delay could pressure margins.
Q1 FY25 · mediumSemaglutide patent expiry in 2026 may shift patients from liraglutide to newer GLP-1s, potentially limiting liraglutide's revenue potential.
Q1 FY25 · mediumCFO guided working capital days to increase to ~75 days from current 62 days, driven by business growth and receivables, which could pressure cash flows.
Q2 FY25 · mediumUS generic market faces low single-digit price erosion; margins remain under pressure from competition.
Q2 FY25 · mediumLirafit (GLP-1 biosimilar) faced supply issues; resolution expected from December but could impact scaling.
Q3 FY25 · mediumAdverse currency movements in LATAM, South Africa, and Russia impacted reported growth and EBITDA margins by approximately INR 71 crore in Q3.
Q3 FY25 · mediumQ3 India formulation growth was impacted by a slowdown in acute respiratory sales, though management expects recovery in Q4.
Q3 FY25 · mediumThe Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
What changed through the year
Q1 FY25 · Full-year EBITDA margin guidance of ~19%
Management guided to approximately 19% EBITDA margin for FY25, supported by India growth, RYALTRIS ramp-up, and lower R&D spend.
Q1 FY25 · RYALTRIS sales target of $80 million in FY25
Management reiterated the target of $80 million in RYALTRIS sales for the full year, with new market launches expected in FY26.
Q1 FY25 · US recovery expected in H2 FY25
Management expects US business to recover in the second half of FY25, driven by respiratory product approvals and Monroe facility restart.
Q1 FY25 · IGI partnership expected in FY26
Management plans to partner IGI's clinical asset 2001 in FY26 after presenting data at ASH in December 2024.
Q2 FY25 · Full-year EBITDA margin of ~19%
Management expects FY25 EBITDA margin to be close to 19%, with gradual improvement of 1-1.5% per year thereafter.
Q2 FY25 · Monroe plant resumption by end of FY25
Management expects to reinitiate commercial production at Monroe before end of FY25, following FDA meeting.
Q2 FY25 · First respiratory launch in 6-9 months
Glenmark expects to launch its first respiratory product in the US within 6-9 months, pending approval.
Q2 FY25 · IGI partnership for ISB 2001 by FY26
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
Q3 FY25 · India business to achieve 9-10% growth for FY25
Management reiterated guidance of INR 1,100 crore per quarter average, implying 9-10% YoY growth for the full year.
Q3 FY25 · EBITDA margin improvement of 1-1.5% YoY
Management expects year-on-year EBITDA margin improvement of 1-1.5% going forward, driven by critical launches.
Q3 FY25 · Fluticasone 44 MDI approval in H1 FY26
The company expects approval for Fluticasone 44 mcg MDI in the first half of FY26, with potential for earlier approval.
Q3 FY25 · IGI to be self-funded from FY27 onwards
Management expects FY26 to be the last year of Glenmark's capital investment in IGI, with a partnership expected to fund IGI going forward.
Q4 FY25 · Revenue growth 10%-12% in FY26
Consolidated revenue from operations expected to grow 10%-12% year-over-year in FY2026.
Q4 FY25 · EBITDA margin 19%-20% in FY26
EBITDA margin guided to 19%-20% for FY2026, driven by Ryaltris, U.S. launches, and R&D efficiencies.
Q4 FY25 · Cash generation INR 300-400 crore in FY26
Free cash flow (post-interest and dividends) expected to be INR 300-400 crore in FY2026.
Q4 FY25 · Generic Flovent 44 mcg approval by end of Q2 FY26
Expects approval for generic Flovent 44 mcg strength by end of Q2 FY2026, with launch thereafter.